Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tight glucose management reduces the risk of congenital anomalies and other complications
This FDA-approved medication, available in both injectable and oral forms, harnesses the power of the GLP-1 hormone to help suppress appetite and promote significant weight loss
The company launched in November 2024 with a specific mission: provide physician-formulated nutritional support for people using GLP-1 receptor agonist medications for weight management
It validates years of innovative R&D and will soon offer a tailored, evidence-based treatment option for Chinas overweight and obese population. Strategic Partnerships and Future Plans Mazdutide, known as OXM3 in early development, was co-developed under an exclusive licensing agreement between Innovent Biologics and Eli Lilly for the China market
US$ 28.23
US$ 20.93
US$ 27.30
US$ 23.16
US$ 20.25
US$ 21.52
